The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, according to featured clinical research. In the new analysis of data from the SUMMIT trial, researchers focused on patients with obesity, chronic kidney disease and HFpEF. HFpEF occurs when the heart muscle cannot enlarge sufficiently to accommodate the blood it receives, causing pressure in the heart to become elevated. Chronic kidney disease occurs when the kidneys do not filter waste from the blood as they should, leading to a buildup of toxins. Tirzepatide...